Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19780795
DOI
10.1111/j.1528-1167.2009.02305.x
PII: EPI2305
Knihovny.cz E-resources
- MeSH
- Anticonvulsants pharmacology MeSH
- Behavior, Animal drug effects physiology MeSH
- Epilepsy, Tonic-Clonic chemically induced classification physiopathology MeSH
- Infant MeSH
- Spasms, Infantile physiopathology MeSH
- Rats MeSH
- Valproic Acid pharmacology MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- N-Methylaspartate pharmacology MeSH
- Animals, Newborn MeSH
- Rats, Wistar MeSH
- Receptors, N-Methyl-D-Aspartate drug effects MeSH
- Age Factors MeSH
- Vigabatrin pharmacology MeSH
- Seizures chemically induced mortality prevention & control MeSH
- Animals MeSH
- Check Tag
- Infant MeSH
- Rats MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anticonvulsants MeSH
- Valproic Acid MeSH
- N-Methylaspartate MeSH
- Receptors, N-Methyl-D-Aspartate MeSH
- Vigabatrin MeSH
In immature rats, N-methyl-D-aspartate (NMDA) induces several seizure types: flexion seizures (FS; in rats younger than 3 weeks), clonic seizures (in animals older than 3 weeks), and clonic-tonic seizures (CTS; in rats of all ages). FS represent a model of human infantile spasms. Effects of vigabatrin and valproate against all types of NMDA-induced seizures were studied in rats at postnatal days 12 (P12) and 25 (P25). NMDA (60 or 300 mg/kg) was injected to animals pretreated with vigabatrin (300-1,200 mg/kg; 24 h before NMDA) or valproate (100-400 mg/kg; 15 min before NMDA). Vigabatrin suppressed FS in P12 rats, but was ineffective against CTS in both age groups. Valproate suppressed CTS in P12, but not in P25 rats. Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly. Neither drug decreased NMDA-induced mortality, which occurred within approximately 15 min after NMDA administration and reached almost 100% in all groups.
References provided by Crossref.org
